急性白血病中大剂量胸腺肽应用的初步观察

FIRST OBERSVING ON USING HIGH-DOSE THYMOPETIDE IN ACUTE LEUKEMIA

目的：观察大剂量胸腺肽对急性白血病化疗患者院内感染的干预作用及其作用机制。方法：42例患者在化疗的同时使用大剂量的胸腺肽治疗(200mg／d静脉滴注,连用14d～18d)，对照组单独使用化疗，方案与观察组相同。对两组患者的感染率、死亡率进行调查。对治疗前后的细胞免疫功能进行检测并进行相应的统计学处理。结果：观察组院内感染率及病死率明显低于对照组(P<0．05及P<0．01)，治疗后观察组患者的细胞免疫功能(T4,T4/T8及NK细胞活性)明显高于对照组(P<0．05及P<0．01)。结论：大剂量胸腺肽在增加化疗效果的同时可显著增强机体的细胞免疫功能。增加机体的抗感染能力，降低院内感染的发生率及相关死亡率。

Objective:To observe the influence of high-dose thymopeptide on hospital infection and cellular immunity in patients with acute leukemia during chemotherapy.Methods:To observe group of42cases accepted high-dose thymopeptide and chemotherapy concurrently while the controlled group of48cases only chemotherapy the rate of acquired hospital infection and mortality as well as the variation of cel-lular immunity were investigated in all patients after treatment.Results:The rate of acquired hospital in-fection and mortality in observed group were more lower than that of controlled group(P<0.05and P<0.01),and the cellular immunity especially the content of T 4 (CD 4 )and the rate of T 4 /T 8 as well as NK cell activity were elevated considerably in observed patients(P<0.05and P<0.01).Conclusion:High-dose thymopeptide is very effective in acute leukemia during chemotherapy,it can be reduce the rate of of acquired hospital in-fection and related mortality and improve cellular immunity concurrently.